Shutterstock
Campbell Bunce, Chief Scientific Officer (CSO) and Cambridge Site Head at Abzena
When ADCs Team Up with Immune Modulators to Fight Cancer
Campbell Bunce, Chief Scientific Officer and Cambridge Site Head at Abzena looks at how ADCs are being integrated with the capacity to modulate the immune system and how this marks a progressive shift in the fight against cancer.
Published:
|
7 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.